L-701,324

Pricing Availability   Qty
Description: NMDA antagonist; acts at glycine site
Chemical Name: 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(1H)-quinolinone
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (5)

Biological Activity for L-701,324

L-701,324 is a an orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.

Licensing Information

Sold with the permission of Merck Sharp and Dohme Ltd.

Technical Data for L-701,324

M. Wt 363.8
Formula C21H14ClNO3
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 142326-59-8
PubChem ID 54682505
InChI Key FLVRDMUHUXVRET-UHFFFAOYSA-N
Smiles OC1=C(C(=O)NC2=CC(Cl)=CC=C12)C1=CC=CC(OC2=CC=CC=C2)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for L-701,324

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 100

Preparing Stock Solutions for L-701,324

The following data is based on the product molecular weight 363.8. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.75 mL 13.74 mL 27.49 mL
5 mM 0.55 mL 2.75 mL 5.5 mL
10 mM 0.27 mL 1.37 mL 2.75 mL
50 mM 0.05 mL 0.27 mL 0.55 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for L-701,324

Certificate of Analysis / Product Datasheet
Select another batch:

References for L-701,324

References are publications that support the biological activity of the product.

Bristow et al (1996) The atypical neuroleptic profile of the glycine/N-MthD.-aspartate receptor antagonist, L-701,324 in rodents. J.Pharmacol.Exp.Ther. 277 578 PMID: 8627534

Bristow et al (1996) Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-MthD.-aspartate receptor complex. J.Pharmacol.Exp.Ther. 279 492 PMID: 8930150

Kulagowski et al (1994) 3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor. J.Med.Chem. 37 1402 PMID: 8182696

Obrenovitch and Zilkha (1996) Inhibition of cortical spreading depression by L-701,324, a novel antagonist at the glycine site of the N-MthD.-aspartate receptor complex. Br.J.Pharmacol. 117 931 PMID: 8851513


If you know of a relevant reference for L-701,324, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: L-701,324, L-701,324 supplier, NMDA, antagonist, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, L701324, 0907, Tocris Bioscience

1 Citation for L-701,324

Citations are publications that use Tocris products. Selected citations for L-701,324 include:

Bäckström and Hyytiä (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31 778 PMID: 16123768


Do you know of a great paper that uses L-701,324 from Tocris? Please let us know.

Reviews for L-701,324

There are currently no reviews for this product. Be the first to review L-701,324 and earn rewards!

Have you used L-701,324?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.